{"id":3880,"date":"2023-06-29T15:13:04","date_gmt":"2023-06-29T12:13:04","guid":{"rendered":"https:\/\/staging.iasispharma.com\/en\/?p=3880"},"modified":"2023-06-29T16:52:24","modified_gmt":"2023-06-29T13:52:24","slug":"new-product-launching-nitrofurantoiniasis-oral-susp-1st-choice-prevention-treatment-of-utis","status":"publish","type":"post","link":"https:\/\/iasispharma.com\/en\/all-articles\/new-product-launching-nitrofurantoiniasis-oral-susp-1st-choice-prevention-treatment-of-utis\/","title":{"rendered":"NEW PRODUCT LAUNCHING: Nitrofurantoin\/IASIS\u00ae oral susp. &#8211; 1st Choice, Prevention &#038; Treatment of UTIs"},"content":{"rendered":"<p><strong>IASIS PHARMA<\/strong> is pleased to announce the <strong>Nitrofurantoin\/IASIS oral susp.<\/strong> launching in the <strong>oral suspension<\/strong> formulation.<\/p>\n<p>This Innovative Pharmaceutical Form is a global market leader. This dosage form is Research and Development by <strong>IASIS PHARMA HELLAS S.A.<\/strong><\/p>\n<p>Each <strong>5ml<\/strong> of <strong>oral suspension<\/strong> Nitrofurantoin\/IASIS oral susp. <strong>contains 25mg<\/strong> of <strong>Nitrofurantoin monohydrate<\/strong> which, according to international literature, is the <strong>1st Choice in the Global Guidelines for the Prevention <\/strong>&amp;<strong> Treatment of Uncomplicated UTIs<\/strong>.<\/p>\n<p><strong>Nitrofurantoin\/IASIS oral susp.<\/strong> is available in the market in the two pack sizes of <strong>150ml <\/strong>&amp; <strong>300ml<\/strong> respectively, <strong>indicated mainly for the<\/strong> <strong>treatment <\/strong>&amp; <strong>prophylaxis<\/strong> against <strong>acute or recurrent<\/strong>, <strong>uncomplicated lower urinary tract infections<\/strong> or pyelitis, either spontaneous or after surgical operations. It is specifically indicated for the <strong>treatment of infections<\/strong> caused by <strong>resistant strains<\/strong> of Escherichia coli, Enterococci, Staphylococci, Citrobacter, Klebsiella and Enterobacter.<\/p>\n<p><strong>Nitrofurantoin\/IASIS oral susp.<\/strong> is indicated for use in <strong>adults<\/strong> and <strong>children<\/strong> <strong>over three months of age<\/strong>.<\/p>\n<p>It is promoted by <strong>PharmaQ<\/strong>, a company of <strong>IASIS PHARMA HELLAS S.A.<\/strong><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IASIS PHARMA is pleased to announce the Nitrofurantoin\/IASIS oral susp. launching in the oral suspension formulation. This Innovative Pharmaceutical Form is a global market leader. This dosage form is Research and Development by IASIS PHARMA HELLAS S.A. Each 5ml of oral suspension Nitrofurantoin\/IASIS oral susp. contains 25mg of Nitrofurantoin monohydrate which, according to international literature,  [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":3838,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":true,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33,157,146],"tags":[],"class_list":["post-3880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-articles","category-press-room-en","category-product-launches"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7HJeP-10A","jetpack_featured_media_url":"https:\/\/iasispharma.com\/wp-content\/uploads\/2023\/06\/pack-shots_2023_clear-Nitrofurantoin-ofiicial_all_website-copy.png","_links":{"self":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/3880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/comments?post=3880"}],"version-history":[{"count":4,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/3880\/revisions"}],"predecessor-version":[{"id":3885,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/3880\/revisions\/3885"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/media\/3838"}],"wp:attachment":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/media?parent=3880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/categories?post=3880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/tags?post=3880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}